Ozempic is best known for shrinking waistlines. It may also be shrinking the likelihood that someone acts on a violent impulse.
A Rutgers University study published June 17, 2026 in the journal Criminology — the flagship peer-reviewed journal of the American Society of Criminology — has found that GLP-1 receptor agonist medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are associated with a substantially weaker link between impulsivity, alcohol use, and violent behavior. The study was highlighted June 23, 2026 on Medscape in a report on what GLP-1s are teaching science about compulsive behavior — underscoring that this finding is now being taken seriously in clinical medicine, not just criminology.
The research was led by Daniel C. Semenza, PhD, director of research at the New Jersey Gun Violence Research Center and associate professor at Rutgers School of Public Health, and co-authored by Christopher Thomas, assistant professor at Rutgers University-Camden. The team analyzed data from a 2025 nationally representative survey of 7,521 U.S. adults, focusing specifically on the 821 individuals who had ever used a GLP-1 medication, including 597 who were currently taking one. Violent behavior was measured using a validated self-reported scale covering assault, armed robbery, and fighting.
The finding was striking. Among current GLP-1 users, the well-established link between impulsivity and violent behavior was approximately 62% weaker than among former users. The relationship between alcohol use and violent behavior was approximately 52% weaker among current users. Both associations remained statistically significant after controlling for demographic and health variables.
What the Numbers Show — and What the Researchers Say They Cannot Claim
The finding demands both serious attention and serious caveats — and the researchers are explicit about both.
"Our findings are consistent with these medications working like cognitive behavioral therapy, weakening the path from impulse to action rather than eliminating impulsivity itself," said Christopher Thomas. The analogy is precise: cognitive behavioral therapy works not by eliminating impulsive thoughts but by inserting a pause between impulse and action. If GLP-1s are doing something similar through neurochemical pathways — acting on reward processing, craving suppression, and dopaminergic systems in the brain — the result may be a chemical equivalent of that trained pause.
Semenza emphasized that the study "was quite surprised with how robust the impulsivity finding was in particular," but was equally direct about limitations: the study is observational and cross-sectional. It cannot establish cause and effect. The sample of GLP-1 users was relatively small at 821. The data is self-reported. And the study was not designed to identify the biological mechanisms driving the association. "We can't say with certainty why these associations emerged in this paper," Semenza told Healthline.
The researchers also cautioned against concluding that any specific GLP-1 drug is "an anti-crime drug." As co-author Christopher Thomas told Vice: "It doesn't eliminate impulsivity; it just weakens the connection between impulsivity and action. You might still feel the need to do something violent; you just won't give in to it."
| Rutgers GLP-1 Violence Study Key Data | Finding |
| Survey sample | 7,521 U.S. adults |
| GLP-1 users analyzed | 821 (597 current, 224 former) |
| Impulsivity-violence link among current vs. former users | ~62% weaker |
| Alcohol-violence link among current vs. former users | ~52% weaker |
| Journal | Criminology (published June 17, 2026) |
| Study type | Observational, cross-sectional |
| Causal conclusion possible | No — associations only |
The Science Behind Why This Makes Biological Sense
GLP-1 receptors are not only found in the pancreas and gut. Growing research has established that GLP-1 receptors are distributed throughout the central nervous system, including in areas involved in reward processing, impulsivity, and decision-making, including the nucleus accumbens, the prefrontal cortex, and the dopamine system broadly. The same neural circuitry that drives compulsive eating also governs responses to alcohol, other addictive stimuli, and the kind of emotional reactivity that can escalate to physical aggression.
GLP-1 medications have already been shown in prior peer-reviewed research to reduce alcohol cravings, gambling urges, and self-reported "food noise" — the constant mental preoccupation with food that drives compulsive eating. If the mechanism is a general dampening of reward-seeking and impulse-to-action pathways rather than a specific food-related effect, the Rutgers findings are biologically coherent. "Growing research suggests that GLP-1 medications may influence things like reward processing and impulse control," Semenza told Healthline. "One potential theory here is that there is something happening in the brain through these drugs that is quieting down that noise and allowing kind of more calmness and a more measured response to things."
The study calls explicitly for future longitudinal and experimental research to determine whether GLP-1 medications truly lower violence risk and to identify the biological mechanisms involved. Both researchers framed the current paper as a first step rather than a definitive answer — a finding significant enough to warrant rigorous follow-up, not to support policy changes without much stronger causal evidence.
Frequently Asked Questions
What did the Rutgers GLP-1 violence study find?
A Rutgers study published June 17 in Criminology found that among current GLP-1 users, the link between impulsivity and violent behavior was approximately 62% weaker than among former users, and the link between alcohol use and violence was 52% weaker. The study analyzed data from 821 GLP-1 users within a nationally representative survey of 7,521 adults.
Does this mean Ozempic prevents violent crime?
No. The study authors were explicit that the research is observational and cross-sectional, meaning it can identify associations but cannot prove causation. The drug is not called an anti-crime drug and should not be framed as one. Further longitudinal and experimental studies are required.
Why might GLP-1 drugs affect impulsive or violent behavior?
GLP-1 receptors are distributed throughout the brain in areas governing reward processing, craving, and impulse control — not just in the pancreas and gut. Prior research has shown GLP-1 drugs reduce alcohol cravings and compulsive behaviors, suggesting the mechanism may be a general dampening of impulse-to-action pathways rather than a food-specific effect.
Who led this research?
The study was led by Daniel C. Semenza, PhD, director of research at the New Jersey Gun Violence Research Center and associate professor at Rutgers School of Public Health, and co-authored by Christopher Thomas, assistant professor at Rutgers University-Camden.
What should people currently taking GLP-1 drugs know about this finding?
The study is preliminary. GLP-1 medications are prescribed for type 2 diabetes and obesity management — not for behavioral or psychiatric conditions. Anyone taking these medications for approved indications should not change their use based on this study. The finding warrants further clinical investigation.
.png?w=600)
